Cartesian Therapeutics (RNAC) Receivables - Net (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Receivables - Net for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Net rose 27.87% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 27.87% increase, with the full-year FY2025 number at $1.1 million, up 27.87% from a year prior.
- Receivables - Net was $1.1 million for Q4 2025 at Cartesian Therapeutics, up from $722000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $32.0 million in Q2 2024 to a low of $354000.0 in Q2 2025.
- A 5-year average of $7.3 million and a median of $6.2 million in 2022 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: skyrocketed 494.97% in 2024, then tumbled 98.9% in 2025.
- Cartesian Therapeutics' Receivables - Net stood at $9.9 million in 2021, then crashed by 33.47% to $6.6 million in 2022, then fell by 11.01% to $5.9 million in 2023, then crashed by 85.14% to $872000.0 in 2024, then increased by 27.87% to $1.1 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Receivables - Net are $1.1 million (Q4 2025), $722000.0 (Q3 2025), and $354000.0 (Q2 2025).